Parkinson's Trial NCT07642908
Link brain chemicals to walking
- Trial ID
- NCT07642908
- Official Title
- Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
- Goal
- Link brain chemicals to walking
- Status
- RECRUITING
- Sponsor
- University of Michigan
- Study Type
- OBSERVATIONAL
- Enrollment
- 15 participants
- Conditions
- Parkinson Disease
Summary For Families
Researchers are studying how a common genetic change called LRRK2 affects brain systems in people with Parkinson's, especially the brain chemical system that supports attention and memory, and whether those differences relate to thinking problems or to balance and walking difficulties. Participants will have whole-brain positron emission tomography scans that map nerve endings that use a key brain chemical, a second PET scan that looks at dopamine nerve terminals, magnetic resonance imaging, and tests of thinking, movement, sensation, and questionnaires so researchers can link brain chemistry with symptoms. They are enrolling people aged 45 and older who have Parkinson's and a confirmed LRRK2 mutation; people who cannot have magnetic resonance imaging, who regularly take certain anticholinergic or memory drugs, who have had deep brain stimulation, who are pregnant or unable to consent, or who have other major health or safety issues are not eligible.
Locations
- University of Michigan, Ann Arbor, Michigan, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. Researchers are studying how a common genetic change called LRRK2 affects brain systems in people with Parkinson's, especially the brain chemical system that supports attention and memory, and whether those differences relate to thinking problems or to balance and walking difficulties. Participants will have whole-brain positron emission tomography scans that map nerve endings that use a key brain chemical, a second PET scan that looks at dopamine nerve terminals, magnetic resonance imaging, and tests of thinking, movement, sensation, and questionnaires so researchers can link brain chemistry with symptoms. They are enrolling people aged 45 and older who have Parkinson's and a confirmed LRRK2 mutation; people who cannot have magnetic resonance imaging, who regularly take certain anticholinergic or memory drugs, who have had deep brain stimulation, who are pregnant or unable to consent, or who have other major health or safety issues are not eligible.
- Who can participate?
- Participants must be at least 45 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: PET scan (minimally invasive); MRI scan (non-invasive); Questionnaires & surveys (non-invasive); Walking & movement tests (non-invasive); Thinking & memory tests (non-invasive). Confirm the full schedule with the study coordinator.